EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia

Ahmad Alam, Mohd Salman

Bangladesh Journal of Endocrinology and Metabolism · 2026-09 · 5 (3) · 277-281

DOI: 10.4103/bjem.bjem_31_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bangladesh Journal of Endocrinology and Metabolism, online erschienen am 06.07.2026. Verfasst von Ahmad Alam und 1 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity in Asian populations is characterized by a distinctive metabolic phenotype, with insulin resistance, visceral adiposity, metabolic dysfunction-associated steatotic liver disease, and type 2 diabetes often developing at lower body mass index thresholds than in White populations, highlighting the need for population-specific therapeutic evidence. In this context, STEP-7 and GLORY-1 provide important East Asian data on semaglutide 2.4 mg and mazdutide, respectively. Semaglutide acts through selective glucagon-like peptide-1 (GLP-1) receptor agonism, whereas mazdutide combines GLP-1 and glucagon receptor agonism, providing a mechanistic rationale for effects beyond appetite suppression alone. In STEP-7, semaglutide was associated with a mean body-weight reduction of 12.1% at 44 weeks, whereas GLORY-1 demonstrated dose-dependent weight loss with mazdutide, with reductions of 11.0% at 4 mg and 14.01% at 6 mg over 48 weeks. GLORY-1 also reported marked reductions in liver fat, suggesting potential relevance in patients with obesity complicated by hepatic steatosis or broader metabolic dysfunction. Emerging data from DREAMS-3 and the GLORY program are promising, but whether mazdutide can translate its early efficacy into durable cardiovascular, renal, and metabolic benefits beyond those of GLP-1 receptor agonists remains to be established.

Zitieren

APA

Alam, A., & Salman, M. (2026). Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia. Bangladesh Journal of Endocrinology and Metabolism, 5(3), 277-281. https://doi.org/10.4103/bjem.bjem_31_26

Vancouver

Alam A, Salman M. Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia. Bangladesh Journal of Endocrinology and Metabolism. 2026;5(3):277-281. doi:10.4103/bjem.bjem_31_26

BibTeX
@article{Alam2026,
  author = {Alam, Ahmad and Salman, Mohd},
  title = {Mazdutide in Asian Obesity: Mechanistic Rationale, Emerging Clinical Evidence, and Relevance to South Asia},
  journal = {Bangladesh Journal of Endocrinology and Metabolism},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {277--281},
  doi = {10.4103/bjem.bjem_31_26}
}
Kostenlos starten →